Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Sleeping beauty system to redirect T-cell specificity for human applications.

Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ.

J Immunother. 2013 Feb;36(2):112-23. doi: 10.1097/CJI.0b013e3182811ce9.

2.

Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.

Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ.

PLoS One. 2013 May 31;8(5):e64138. doi: 10.1371/journal.pone.0064138. Print 2013.

3.

Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ.

Mol Ther. 2013 Mar;21(3):638-47. doi: 10.1038/mt.2012.267. Epub 2013 Jan 8.

4.

Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.

Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ.

J Vis Exp. 2013 Feb 1;(72):e50070. doi: 10.3791/50070.

5.

The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor.

Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ.

Gene Ther. 2011 Sep;18(9):849-56. doi: 10.1038/gt.2011.40. Epub 2011 Mar 31.

6.

The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.

Tsukahara T, Iwase N, Kawakami K, Iwasaki M, Yamamoto C, Ohmine K, Uchibori R, Teruya T, Ido H, Saga Y, Urabe M, Mizukami H, Kume A, Nakamura M, Brentjens R, Ozawa K.

Gene Ther. 2015 Feb;22(2):209-15. doi: 10.1038/gt.2014.104. Epub 2014 Nov 27.

PMID:
25427612
7.

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovich B, Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJ.

Blood. 2012 Jun 14;119(24):5697-705. doi: 10.1182/blood-2012-01-405365. Epub 2012 Apr 24. Erratum in: Blood. 2015 Nov 26;126(22):2527. Rabinovitch, Brian [corrected to Rabinovich, Brian].

8.

Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ.

Cancer Res. 2008 Apr 15;68(8):2961-71. doi: 10.1158/0008-5472.CAN-07-5600.

9.

piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ.

Hum Gene Ther. 2010 Apr;21(4):427-37. doi: 10.1089/hum.2009.114.

10.

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.

Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ.

Hum Gene Ther. 2012 May;23(5):444-50. doi: 10.1089/hum.2011.167. Epub 2012 Jan 17.

11.

Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.

Singh H, Moyes JS, Huls MH, Cooper LJ.

Cancer Gene Ther. 2015 Mar;22(2):95-100. doi: 10.1038/cgt.2014.69. Epub 2015 Jan 16. Review.

PMID:
25591810
12.

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ.

Cancer Res. 2011 May 15;71(10):3516-27. doi: 10.1158/0008-5472.CAN-10-3843. Epub 2011 May 10. Erratum in: Cancer Res. 2011 Jul 1;71(13):4734.

13.

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Singh H, Huls H, Kebriaei P, Cooper LJ.

Immunol Rev. 2014 Jan;257(1):181-90. doi: 10.1111/imr.12137. Review.

14.

Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.

Huang X, Guo H, Kang J, Choi S, Zhou TC, Tammana S, Lees CJ, Li ZZ, Milone M, Levine BL, Tolar J, June CH, Scott McIvor R, Wagner JE, Blazar BR, Zhou X.

Mol Ther. 2008 Mar;16(3):580-9. doi: 10.1038/sj.mt.6300404. Epub 2008 Jan 29.

15.

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.

Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ.

PLoS One. 2013;8(3):e57838. doi: 10.1371/journal.pone.0057838. Epub 2013 Mar 1.

16.

Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Saito S, Nakazawa Y, Sueki A, Matsuda K, Tanaka M, Yanagisawa R, Maeda Y, Sato Y, Okabe S, Inukai T, Sugita K, Wilson MH, Rooney CM, Koike K.

Cytotherapy. 2014 Sep;16(9):1257-69. doi: 10.1016/j.jcyt.2014.05.022.

17.

A transposon and transposase system for human application.

Hackett PB, Largaespada DA, Cooper LJ.

Mol Ther. 2010 Apr;18(4):674-83. doi: 10.1038/mt.2010.2. Epub 2010 Jan 26. Review.

18.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Kochenderfer JN, Rosenberg SA.

Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2. Review.

PMID:
23546520
19.

A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.

Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ.

Biomed Microdevices. 2010 Oct;12(5):855-63. doi: 10.1007/s10544-010-9440-3.

20.

Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.

Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S, Dai J, Lee D, Cooper LJ.

J Immunother. 2014 May;37(4):204-13. doi: 10.1097/CJI.0000000000000032.

Supplemental Content

Support Center